7.350

-0.110 (-1.47%)
Range 6.992 - 7.430   (6.26%)
Open 7.430
Previous Close 7.460
Buy Price 7.350
Buy Volume 361
Sell Price 7.360
Sell Volume 32
Volume 1,343,386
Value -
Remark
Measurement Type Value
EPS (USD) -0.327
Trailing EPS (USD) -0.329
NAV (USD) 1.332
Cash In Hand (USD) 1.213
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 5.601
Price / Cash In Hand 6.15
Issued & Paid-up Shares 91,535,300
Treasury Shares -
Market Cap (M) 682.853
Par Value (USD) n.a.
Beta - 75 Days -2.545
R-Squared - 75 Days(%) 5.47
Beta - 500 Days 0.593
R-Squared - 500 Days(%) 0.28
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 28 Jul 2021 04:00.
Data powered by

Upcoming Events

* Stock event date based on US timezone.

Earnings

Release Date 03 Aug 2021
View All Events

About CURIS INC

Curis, Inc. is a drug discovery and development company that is committed to leveraging signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies. The Company conducts its research and development programs both internally and through strategic collaborations. Its advanced program is Hedgehog pathway inhibitor program under collaboration with Genentech, Inc., a wholly owned member of the Roche Group. The lead drug candidate being developed under this program is Erivedge, a orally-administered small molecule Hedgehog pathway inhibitor, which is also known as vismodegib, GDC-0449 and RG3616. In October 2011, the Company completed a Phase Ib expansion trial to test CUDC-101. The Company�s other development candidate under collaboration is Debio 0932 (formerly CUDC-305).

There are 3 followers

Followers
0
Followers
0
Followers
0